Hybrid Molecules in Drug Discovery from Antidiabetic Agents to Anticancer Therapeutics

Dear Colleagues,

Hybrid molecules, which integrate two or more pharmacophores into a single chemical entity, have emerged as a powerful strategy in modern drug discovery. This approach leverages the synergistic potential of distinct bioactive fragments to achieve enhanced efficacy, improved pharmacokinetic properties, and reduced adverse effects compared to traditional single target agents. By simultaneously modulating multiple molecular pathways, hybrid compounds hold promise for addressing the complexity of multifactorial diseases such as diabetes, and cancer.

In the context of antidiabetic drug development, hybrid molecules can effectively target hyperglycemia, insulin resistance, and associated complications through combined mechanisms such as enzyme inhibition, receptor modulation, and antioxidant activity. Similarly, in oncology, hybrid therapeutics provide opportunities to overcome multidrug resistance, induce selective cytotoxicity, and synergistically disrupt tumor growth and metastasis. The versatility of hybrid design not only expands the chemical and biological space for drug development but also paves the way for personalized and multi target therapies.

This Special Issue highlights the latest advances in the design, synthesis, and biological evaluation of hybrid molecules, spanning preclinical studies to translational applications. By showcasing interdisciplinary contributions, it aims to deepen our understanding of structure activity relationships, promote innovative therapeutic concepts, and accelerate the path toward next generation treatments. Ultimately, hybrid drug discovery stands at the forefront of precision medicine, offering novel solutions for some of the most pressing health challenges of our time.

Dr. Jatinder Singh
Dr. Shreyosree Chatterjee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.